Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03776864
Title Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab + Umbralisib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.